OncoMatch/Clinical Trials/NCT07257419
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Is NCT07257419 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for relapsed pediatric all.
Treatment: Anti-Thymocyte Globulin (Rabbit) · Cyclophosphamide · Fludarabine · Thiotepa · Mesna · Melphalan · Filgrastim · CliniMACS System — The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL. Primary Objective: \- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies. Secondary Objectives: * To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS). * To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Received a prior allogeneic HCT at any time
Lab requirements
Kidney function
creatinine clearance (crcl) or glomerular filtration rate (gfr) ≥ 50 ml/min/1.73m2
Liver function
bilirubin ≤ 3 times the upper limit of normal for age; alt or ast ≤ 5 times the upper limit of normal for age
Cardiac function
left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07257419 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplant disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify